pharmacology

A new clinical trial suggests the weight-loss drug semaglutide could help treat alcohol use disorder. While it didn't eliminate laboratory-assessed cravings, the medication significantly reduced heavy drinking days and overall alcohol-related problems in treatment-seeking adults.

Around 2 percent of the world's population has to live with the severe hair loss...

GLP-1 drugs like Wegovy and Ozempic are never out of the headlines for long. They've...

A new study suggests that consuming psilocin directly—rather than its precursor, psilocybin—provides a similar psychedelic experience with fewer side effects. Researchers also found that taking the drug under the tongue produced emotional breakthroughs despite milder effects.

For many people, losing weight with a GLP-1 medicine brings major improvements in blood sugar, weight and overall health. But hair thinning has become an increasingly discussed concern among people using drugs such as Ozempic, Wegovy and Zepbound. A new study from researchers at NYU Langone Health offers a possible explanation for at least some […] The post Why Some Men on Weight Loss Drugs Get H…

Not all older people need these medications, and they can carry increased risks.

Explore KRAS inhibitor resistance mechanisms: intrinsic vs adaptive pathways, lineage plasticity, multi-bypass alterations, and repeat tissue biopsy care.

[US FDA] The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.

Medicines Discovery Catapult provided its investment and expert support to help two biotech companies accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases. The post Medicines Discovery Catapult Backs Two U.K. Biotech Companies Tackling Chronic Diseases appeared first on GEN - Genetic Engineering and Biotechnology News .

Although the number of US children under age 12 with obesity being prescribed the weight loss drugs Saxenda, Wegovy, and Zepbound remains low, the number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed, a new study shows.

Despite the therapeutic promise of natural plants in preclinical models, their clinical value for heart failure (HF) remains unconfirmed and requires rigorous validation through well-designed trials. HF severely impairs quality of life, and natural plant therapies—known for their multi-metabolites and multi-target effects—have been explored as potential treatments via modulation of autophagy, inh…

Radiotheranostic agents enable paired diagnostic imaging and targeted radiopharmaceutical therapy through the selection of appropriate radioisotopes. Radiotheranostics are typically composed of a targeting vector, a chelator or prosthetic group for radiolabeling and an optional linker for optimizing their pharmacokinetic properties. The chemokine receptor 4 (CXCR4) is a promising target for molec…

After the failure of an experimental drug for Angelman syndrome, experts cautioned that there is still reason to think similar experimental medicines can succeed.